Cilta-cel Garners More Positive Data in Early and Late Relapsed ...

Patients with early relapse after standard multiple myeloma therapies have a poor prognosis. CAR T-cell therapy cilta-cel showed positive results in second-line treatment for early relapsed disease, as presented at the ASH 2022 meeting, offering hope for this patient population.